Traws Pharma (TRAW) Liabilities and Shareholders Equity (2012 - 2026)

Traws Pharma (TRAW) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $8.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 57.22% year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $46.8 million (down 34.63% YoY), while the FY2025 annual figure was $10.6 million, down 57.47% from the prior year.
• Liabilities and Shareholders Equity slipped to $8.2 million in Q1 2026 per TRAW's latest filing, from $10.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $51.4 million in Q1 2022 and bottomed at $8.2 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $25.6 million across 5 years, with a median of $22.7 million in 2023.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 66.95% — and 2025, when it surged 39.25%.
• Traws Pharma's Liabilities and Shareholders Equity stood at $39.4 million in 2022, then sank by 42.39% to $22.7 million in 2023, then gained by 10.05% to $25.0 million in 2024, then slumped by 57.47% to $10.6 million in 2025, then fell by 23.18% to $8.2 million in 2026.
• Business Quant data shows TRAW's Liabilities and Shareholders Equity at $8.2 million in Q1 2026, $10.6 million in Q4 2025, and $12.4 million in Q3 2025.